Quest Pharmatech

Quest Pharmatech Interest Coverage

The Interest Coverage Ratio of Quest Pharmatech (QPT.V) as of Oct 26, 2026 is -0.64. In the previous year, Interest Coverage Ratio was -0.70 — a change of -9.39% (higher).

Interest Coverage

-0.64

YoY

-9.39%

Last updated:

Interest Coverage Ratio of Quest Pharmatech is 2025 -0.64 . Interest Coverage Ratio of Quest Pharmatech was 2024 -0.70 . It decreases by -9.39% higher compared to the previous year.

The Quest Pharmatech Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2018
-7.73 CAD
Jan 1, 2019
-71.99 CAD
Jan 1, 2020
-35.87 CAD
Jan 1, 2021
-0.02 CAD
Jan 1, 2022
-0.01 CAD
Jan 1, 2023
-0.01 CAD
Jan 1, 2024
-0.70 CAD
Jan 1, 2025
-0.64 CAD
The Quest Pharmatech Interest Coverage history
YEARInterest CoverageYoY
-0.64-9.39%
-0.70+5,332.37%
-0.01+38.26%
-0.01-45.29%
-0.02-99.95%
-35.87-50.17%
-71.99+831.71%
-7.73-81.58%
-41.95+5,334.68%
-0.77-96.39%
-21.38+12.32%
-19.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quest Pharmatech Stock analysis

What does Quest Pharmatech do? Quest PharmaTech, Inc. operates as a biotechnology company headquartered in Edmonton, Alberta, focusing on the development and commercialization of antibody-based immunotherapeutic products for cancer. The firm aims to improve the quality of life through its proprietary MAb-AR9.6, which targets MUC16 as a diagnostic agent. This asset is licensed from the University of Nebraska Medical Centre and is currently in the late preclinical stage of development. The company generates value through strategic equity positions in specialized biotechnology entities. Quest PharmaTech holds a 42.5% ownership interest in OncoQuest Inc., a firm developing combinatorial immunotherapy products for cancer treatment. OncoQuest utilizes a technology platform featuring a panel of tumor antigen specific monoclonal antibodies of the immunoglobulin G and E class, targeting CA125, MUC1, PSA, Her2/neu, CA 19.9, and TAG72 to enhance tumor specific immunity. Additionally, the firm maintains a 23% ownership interest in OncoVent, which is developing antibody-based immunotherapeutic products for cancer within the Greater China territory. These investments allow Quest PharmaTech to extend its reach into specific geographic and therapeutic segments while leveraging the proprietary technologies and platforms of its partner companies. Quest Pharmatech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quest Pharmatech stock

Interest Coverage Ratio of Quest Pharmatech is -0.64 in 2025.

Interest Coverage Ratio of Quest Pharmatech changed from -0.70 to -0.64, representing a -9.39% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Quest Pharmatech since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Quest Pharmatech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Quest Pharmatech

All Key Metrics — Quest Pharmatech